Summary: Australia has become the first country to allow the wide prescription of MDMA for the treatment of PTSD, a move that has sparked both support and concern. The decision, made by the country’s drug regulator, the Therapeutic Goods Administration, has positioned Australia as a nationwide experiment for other jurisdictions, such as the United States, to observe. Critics express concern over the lack of a comprehensive regulatory framework and potential risks to patients, while supporters see the potential for relief for individuals suffering from severe mental illnesses.
Australia: The First Country to Authorize MDMA for PTSD Treatment
Australia has recently made history by becoming the first country to authorize psychiatrists to prescribe MDMA as a treatment for post-traumatic stress disorder (PTSD). This decision was made by the Therapeutic Goods Administration (TGA), the country’s drug regulator, which has reclassified MDMA from a prohibited substance to a controlled substance starting from July.
The surprising move has caught the attention of health institutions within Australia and has positioned the country as a nationwide experiment for other jurisdictions, such as the United States, to observe. The decision has sparked both support and concern among experts and the public. Supporters believe that this development could potentially provide relief for individuals suffering from severe mental illnesses.
However, critics express apprehension regarding the lack of a comprehensive regulatory framework and the potential risks associated with prescribing MDMA for PTSD treatment. The TGA has provided some guidance, but its involvement in overseeing MDMA and psilocybin therapies has now largely ceased. Instead, human research ethics committees will be responsible for assessing psychiatrists’ applications to become authorized prescribers, with final TGA sign-off.
One of the concerns expressed by experts is equality of access: Treatments are initially expected to cost about $17,000 for those incorporating standard therapy sessions before and after the drug is taken and multiple dosing sessions lasting about eight hours each. Another concern is the potential for boundaries to be crossed. Australian clinics planning on offering MDMA therapy for PTSD said they would be adapting from the treatment manual published by MAPS, the organization that has applied for FDA approval.
Despite the concerns, the apparent potential of MDMA to help people who have not responded to other treatment is attractive to many. We will continue to follow closely on this subject.
[Source: The Washington Post].
Subscribe to our newsletter
We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!
Simply place your email below:
.
.
AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.
